Aug 08, 2017 10:05 am UTC| Business
Second quarter marked by significant clinical progress with compelling overall Phase 2 data from two studies of flagship product candidate MAT2203Company plans to engage FDA to review overall data package generated with...
Hawaiian Telcom Reports Second Quarter 2017 Results
Aug 08, 2017 10:00 am UTC| Business
Increased TV subscribers by 12 percent, recording 20th consecutive quarter of growthGrew Next-Generation Network penetration on Oʻahu to over 24 percentSuccessfully completed end-to-end testing of the SEA-US submarine...
Lamar Advertising Company Announces Second Quarter 2017 Operating Results
Aug 08, 2017 10:00 am UTC| Business
Three Month Results Net revenue increased 2.5% to $397.1 millionNet income was $92.4 million, an increase of 12.8%Adjusted EBITDA increased 3.1% to $181.9 million Three Month Acquisition-Adjusted Results ...
Aug 08, 2017 10:00 am UTC| Business
RadNet reports record Revenue and EBITDA performanceTotal Net Revenue increased 5.2% to $230.0 million in the second quarter of 2017 from $218.6 million in the second quarter of 2016Adjusted EBITDA(1) increased 5.5% to...
Veru Inc. Reports Fiscal Third Quarter Financial Results
Aug 08, 2017 10:00 am UTC| Business
MIAMI, Aug. 08, 2017 -- Veru Inc. (Nasdaq:VERU) (formerly, Nasdaq:FHCO) (”Veru” or the “company”), formerly known as Veru Healthcare/The Female Health Company, a biopharmaceutical company focused on urology and...
Tesco Corporation Reports Second Quarter 2017 Results
Aug 08, 2017 10:00 am UTC| Business
Liquidity of $72.5 million and no debt at the end of the second quarter, after funding approximately $5 million of working capital growth during the second quarterReported U.S. GAAP diluted EPS was a loss of $(0.26) on a...
Galena Biopharma Enters into Merger Agreement with SELLAS Life Sciences Group
Aug 08, 2017 10:00 am UTC| Business
Merger to create a late-stage, NASDAQ-listed company focused on developing novel immune therapies for various types of cancerSELLAS’ lead asset, galinpepimut-S (GPS), is a Wilm’s Tumor 1 (WT1)-targeting peptide-based...